- Home
- GRRR vs IVA Comparison
GRRR vs IVA Comparison
Compare GRRR & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRRR
- IVA
- Stock Information
- Founded
- GRRR 2001
- IVA 2011
- Country
- GRRR United Kingdom
- IVA France
- Employees
- GRRR N/A
- IVA N/A
- Industry
- GRRR Computer Software: Prepackaged Software
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- GRRR Technology
- IVA Health Care
- Exchange
- GRRR Nasdaq
- IVA Nasdaq
- Market Cap
- GRRR 312.8M
- IVA 359.6M
- IPO Year
- GRRR N/A
- IVA 2020
- Fundamental
- Price
- GRRR $16.13
- IVA $3.62
- Analyst Decision
- GRRR Buy
- IVA Strong Buy
- Analyst Count
- GRRR 1
- IVA 4
- Target Price
- GRRR $18.00
- IVA $10.50
- AVG Volume (30 Days)
- GRRR 1.4M
- IVA 19.8K
- Earning Date
- GRRR 03-31-2025
- IVA 03-26-2025
- Dividend Yield
- GRRR N/A
- IVA N/A
- EPS Growth
- GRRR N/A
- IVA N/A
- EPS
- GRRR N/A
- IVA N/A
- Revenue
- GRRR $74,674,030.00
- IVA $14,591,573.00
- Revenue This Year
- GRRR $36.59
- IVA $15.38
- Revenue Next Year
- GRRR $30.68
- IVA $24.22
- P/E Ratio
- GRRR N/A
- IVA N/A
- Revenue Growth
- GRRR 15.43
- IVA N/A
- 52 Week Low
- GRRR $2.09
- IVA $1.53
- 52 Week High
- GRRR $44.15
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- GRRR 42.71
- IVA 56.12
- Support Level
- GRRR $14.32
- IVA $3.40
- Resistance Level
- GRRR $15.64
- IVA $3.77
- Average True Range (ATR)
- GRRR 1.37
- IVA 0.25
- MACD
- GRRR -0.06
- IVA -0.04
- Stochastic Oscillator
- GRRR 27.55
- IVA 43.79
About GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is primarily engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.